The frequencies of low MBL haplotypes were significantly higher in severe malaria (14.2%) compared to mild malaria (7.9%) and asymptomatic (3.8%). The MBL2*LYPA haplotypes confer protection, whereas MBL2*LXPA increases the malaria risk. Our findings in Indian populations demonstrate that MBL2 functional variants are strongly associated with malaria and infection severity.
M
alaria is one of the major causes of morbidity and mortality in tropical and subtropical countries, with an estimated 1.24 million mortality in 2010, mostly in Africa (1, 2) . Human malaria is caused by the hematoprotozoan parasite of the genus Plasmodium with five different species (i.e., P. falciparum, P. vivax, P. ovale, P. malariae, and P. knowlesi) infecting humans. The pathogenesis of malaria is complex and multigenic, and the severity depends on the complex interplay between host genetic makeup, the parasite virulence, and its transmission dynamics, as well as the host immune responses (3, 4) . Innate immune components mediate humoral immune responses to malaria by involving various complement proteins (5, 6) . The innate immune system mainly relies on diverse pattern-recognizing receptor or soluble pathogen-recognizing molecules (PRMs) (7, 8) that recognize molecular motifs on the surfaces of microorganisms. Mannosebinding lectin (MBL) is a C-type soluble PRMs secreted by the liver as part of the acute-phase response and plays an important role in the recognition, initiation, regulation, and amplification of innate immune defense (9) . The human MBL encoded by MBL2 mapped to 10q21.1 is a 32-kDa polypeptide, made up of 248 amino acids, having an N-terminal cysteine-rich segment, a collagen-like domain, a helical coiled-coil neck region, and a C-terminal glucoconjugate recognition domain (10) . The structural subunit is a homotrimer of 96 kDa with a triple helix at its collagen-like domain. The functional MBL complex is a bouquet-like hexamer that circulates in serum (11, 12) . MBL binds to an array of glycoconjugates on the surface of bacteria, yeasts, viruses, and parasitic protozoa, including P. falciparum (13) , and activates the complement system. MBL interacts with MBL-associated serine proteases (MASP-1, -2, and -3 and Map19) and activates the membrane attack complex or complement-mediated phagocytosis (9, 11, 13) and also regulates the release of proinflammatory cytokines (14) . MBL2 genetic variants have been shown to associate with many infectious diseases such as malaria, leishmaniasis, leprosy, schistosomiasis, trypanosomiasis, HIV infection, and autoimmune disease (9, (14) (15) (16) (17) (18) (19) (20) (21) . Three single-nucleotide polymorphisms (SNPs) in promoters and a 5= untranslated region [(Ϫ550:rs11003125: GϾC, H/L), (Ϫ221:rs7096206 GϾC, Y/X), and (ϩ4:rs7095891 CϾT, P/Q)] are functionally characterized to alter the transcriptional levels and hence the serum MBL levels (22) (23) (24) . In particular, promoter alleles Ϫ550L, Ϫ221X, and ϩ4P are associated with lower MBL serum levels (13) , whereas three nonsynonymous structural variants in exon1 of MBL2 at codons 52, 54, and 57 of the collagen-like domain [(rs5030737: p.Arg52Cys:MBL2*D), (rs1800450: p.Gly54Asp:MBL2*B), and (rs1800451: p.Gly57Glu: MBL2*C)] independently interfere with the formation of higher MBP oligomers, leading to alterations in the functional activity of the protein and their circulating levels (11, (25) (26) (27) (28) (29) (30) . Such structural variant alleles have been designated as O haplotype, whereas the normal MBL2 allele has been designated as A haplotype (31) . Further, these six SNPs (L/H, X/Y, P/Q, MBL2*D, MBL2*B, and MBL2*C) have been shown to be in linkage disequilibrium (LD) and form eight common "secretor haplotypes" (HYPA, LYPA, LYQA, LXPA, HYPD, LYPB, LYQC, and LYPD) (8, 25, 32) . These secretor haplotypes not only regulate the serum levels of functional MBL molecule but also modulate the complement activation (22, 26, 27, 33, 34) . MBL2*HYPA, LYQA, and LYPA are associated with high expression of MBL protein, whereas MBL2*LXPA, HYPD, LYPB, and LYQC are associated with low expression of MBL protein (32, 35) and modulate the MBL concentration in healthy individuals from undetectable levels to 1,000-fold (36, 37) .
To the best of our knowledge, no studies to date have investigated the association of MBL2 functional variants with malarial susceptibility in Indian populations. We sought here to investigate the contribution of polymorphisms in the entire MBL2 gene with P. falciparum malaria infection in well-defined malaria cases and in matched controls. Moreover, Indian populations are unique in their origin and have developed unique variations due to isolation from rest of the world for thousands of years (38, 39) . Since the entire Indian subcontinent represents an area where malaria is endemic, we extended our study to 32 socially, linguistically, and geographically diverse endogamous Indian populations who live in this region.
Medical College, Raipur, Chhattisgarh, India, all approved the study. Informed written consent was obtained from each individual.
Gene sequencing. Genomic DNA was isolated from whole blood according to a previously described protocol (44) . The reference genomic sequences were obtained from the Ensembl database under Ensembl ID ENSG00000165471 (www.ensembl.org). PCR and sequencing primers were designed using NCBI Primer-BLAST (http://www.ncbi.nlm.nih.gov /tools/primer-blast), MacVector (MacVector, Inc., USA), and Amplify 3X software (http://engels.genetics.wisc.edu/amplify). We resequenced 8.7 kb of the MBL2 gene, which includes ϳ1 kb each of the upstream and downstream regions. The target regions of MBL2 were PCR amplified using the primer pairs MBL2_F (5=-ATTACCCTGACCCAGGCCACTG TCTTCT-3=) and MBL2_R (5=-TACATAACATTGACCCCAAACCATA GCAAG-3=). PCR amplifications were performed on a GeneAmp 9700 (Applied Biosystems) and using a thermal cycler (Eppendorf) with a longrange PCR kit (Qiagen, Germany) according to the manufacturer's protocol. The thermal cycling parameters consisted of an initial denaturation at 93°C for 3 min, followed by 35 cycles of 45 s at 93°C, 25 s at 66°C, and 9 min at 68°C.
Only the upstream promoter and first exonic regions (ϳ1.4 kb) were resequenced for population samples. We PCR amplified the target region using two primer pairs-MBL2_UPE1_1F (5=-TCTGTGACTTTCCTCC ATTATCTGT-3=)/MBL2_UPE1_1R (5=-TGGAAGACTATAAACATGC TTTCGG-3=) and MBL2_UPE1_2F (5=-CATTCTCATTCCCTAAGCTA ACAGG-3=)/MBL2_UPE1_2R (5=-CTGGCAAGACAACTATTAGTCAC AA-3=)-and an Emerald PCR master mix (TaKaRa). The thermal cycling parameters consisted of an initial denaturation at 95°C for 5 min, followed by 35 cycles of 30 s at 95°C, 25 s at 62°C, and 3 min at 72°C. PCR amplification was followed by Exo-SAP treatment (USB Corp., USA) according to the manufacturer's protocol. Exo-SAP-treated amplicons were sequenced directly by using a BigDye Terminator v3.1 cycle sequencing kit (Applied Biosystems) on an ABI 3730xl DNA analyzer. The 8.7-kb fragments were sequenced using 17 internal primers (see File S1 in the supplemental material). Sequence variations were identified by assembling DNA sequences with the reference sequence using AutoAssembler software (Applied Biosystems). Variations obtained were validated and reconfirmed in a subset of samples by resequencing and visual confirmation of electropherograms. Novel haplotypes were reconfirmed by subsequent resequencing. Statistical analysis. Risk estimates of severe and mild malaria were derived by comparison to the asymptomatic control group. We compared genotype, allele, and haplotype distributions for (i) asymptomatic versus mild-malaria groups, (ii) asymptomatic versus severe-malaria groups, and (iii) mild-malaria versus severe-malaria groups. The data were analyzed using Intercooled Stata v9.1, and the level of significance was set to a P value of Ͻ0.05. The allele and genotype frequencies were analyzed by simple allele/genotype counting and an expectation-maximum algorithm. The significance of deviations from Hardy-Weinberg (HW) equilibrium was tested using plink v1.7 (45) . The allele and genotype distributions and tests of association were performed using plink. A two-tailed Fisher exact test was performed to determine the differences in allele frequencies and genotype distributions. Linkage disequilibrium (LD) analysis was performed by Haploview v4.2 (46) . Bonferroni corrections were applied for multiple comparisons.
RESULTS
Sequencing of the complete MBL2 gene, along with ϳ1 kb each of the upstream and downstream, led to the detection of a total of 30 polymorphic loci: 29 SNPs and a 6-bp deletion in the promoter region. We observed a novel SNP in the 3= untranslated region at the genomic coordinate position g.54526021CϾA. The genotype and allele distribution of all the variations among the case-control groups is summarized in File S2 in the supplemental material. All observed and investigated loci were in HW equilibrium. The detected variants after exon1 do not significantly contribute in any comparisons. The LD between the promoter and exon1 MBL2 variants in different groups is shown in Fig. 1 . The promoter region of the asymptomatic group was in stronger LD compared to the cases of mild and severe malaria. The genotype and allele distributions observed in different groups and their respective associations are summarized in Table 2 .
Odds of malaria (asymptomatic versus mild malaria). The genotype frequencies of the promoter polymorphism Ϫ221GϾC (rs7096206; MBL2:Y/X) differ significantly between the asymptomatic and mild-malaria groups ( Table 2 ). The frequency of heterozygous genotype YX (Ϫ221GC) was significantly higher in subjects with mild malaria (P ϭ 0.0021) compared to asymptomatic controls (after multiple correction) ( Table 2 and Fig. 2 ). Similarly, the frequency of allele X was significantly higher in patients with mild malaria compared to asymptomatic controls (asymptomatic versus mild, P ϭ 0.0036; Table 2 and Fig. 2 ). These finding suggests that the Ϫ221GC heterozygous bears an increased risk toward mild malaria. None of the other variations were associated with mild malaria (Table 2 and see File S2 in the supplemental material).
Earlier studies demonstrated that the MBL2 serum levels are modulated by Ϫ221 G/C variant and three structural variants of exon1. Therefore, we studied the genotypes of variants in promoter (Ϫ221G/C) and exon1 . We observed that the diplotype YA/YO was significantly low in frequency in the group with mild malaria (P ϭ 0.033) compared to asymptomatic individuals (Table 3 and Fig. 2) .
The reconstructed MBL2 secretor haplotype distributions and their comparison among case-control groups are summarized in Table 4 . Apart from the eight well-known MBL2 secretor haplotypes, we observed four novel MBL2 secretor haplotypes: MBL2*HYQA, MBL2*HYQC, MBL2*LXPB, and MBL2*LYQB. We observed that the low-serum MBL2 haplotype MBL2*LXPA was significantly more frequent in the group with mild malaria compared to the asymptomatic group (P ϭ 0.0045) ( Table 4) . None of the other reconstructed haplotypes contributed significantly to association.
Odds of severe malaria (asymptomatic versus severe malaria). Although the frequency of the heterozygous genotype Ϫ221GϾC (Y/X) was significantly higher in subjects with mild malaria (P ϭ 0.0021), we did not determine its contribution to severe malaria compared to the asymptomatic control (after multiple correction) ( Table 2) . However, the frequency of allele Ϫ221X was significantly higher in patients with severe malaria compared to asymptomatic controls (P ϭ 0.02) ( Table 2 ).
The distribution of the structural variant MBL2*B (rs1800451: codon 54, GϾA) differed significantly between asymptomatic and severe malaria ( Table 2 ). The heterozygous genotype GA (MBL2*AB) was observed significantly at high levels (P ϭ 0.03) compared to asymptomatic controls (Table 2) . Further, the frequency of minor allele A (MBL2*B) was significantly greater in cases of severe malaria (P ϭ 0.036) (after multiple corrections) ( Table 2 ). These findings suggest that the structural variant MBL2*B, which interferes with oligomerization and hence the low level of functional MBL, is a risk factor for P. falciparum malaria (Table 2) . Further, when we grouped all three structural variants of exon1 (MBL2*D/B/C), we observed a significantly higher frequency of heterozygous genotype MBL2*AO (P ϭ 0.0021) compared to the control group. We also observed similar trends in allelic distribution. The frequency of allele MBL2*O was significantly higher in the group with severe malaria (P ϭ 0.0018) compared to the asymptomatic controls (Table 2) . Diplotype analysis shows that the frequency of the high-MBLproducer diplotype (YA/YA) was significantly low (P ϭ 0.00003) in the severe-malaria group compared to asymptomatic controls (Table 3 and Fig. 2) . Similarly, the high MBL2 secretor haplotypes MBL2*LYPA and MBL2*LYQA were significantly less frequent in the severe-malaria group compared to the asymptomatic group (MBL2*LYPA [P ϭ 0.015] and MBL2*LYQA [P ϭ 0.048) (Table 4) . Further, we grouped the MBL2 haplotypes into two groups: the secretor haplotypes that lead to a high level of functional MBL (HYPA ϩ LYQA ϩ LYPA ϩ HYQA) made up one group, and those that lead to a low level (LXPA ϩ LYPB ϩ LYQC ϩ HYPD ϩ LYPD ϩ HYQC ϩ LXPB ϩ LYQB) made up another. We observed a significant difference between asymptomatic subjects and those with severe malaria. The high-MBL-producing haplotypes were significantly less frequent (P ϭ 0.00002), while the low-serum-MBL haplotypes were significantly more frequent (P ϭ 0.00002) in the group with severe malaria compared to the asymptomatic controls ( Table 4) .
Odds of malaria progression (mild malaria versus severe malaria). The exon1 structural variants (MBL2*D, MBL2*B, and MBL2*C) differ significantly between mild and severe malaria cases. We observed that the frequency of the minor allele A at codon 54 (MBL2*B) was higher in severe malaria (P ϭ 0.039) compared to mild malaria (Table 2) . Similarly, the frequency of minor allele A at codon 57 (MBL2*C) was significantly higher in severe-malaria cases than in cases of mild malaria (P ϭ 0.045) ( Table 2 ). The combined genotypes of three structural variants of exon1 show that the allele O (MBL2*D, MBL2*B, and MBL2*C) was significantly more frequent in individuals with severe malaria (P ϭ 0.000045) compared to those with mild malaria (Table 2) .
In line to this observation, the frequency of the high-serum-MBL secretor haplotype MBL2*LYPA was lower in cases of severe malaria than in the mild-malaria group (P ϭ 0.02) ( Table 4 ). This suggests that the exon1 structural variant that affects the oligomerization increases the risk of severe malaria.
MBL2 genotype and haplotype distribution in ethnic populations of India. To characterize MBL2 polymorphisms in different ethnic populations of India, we extended our study to 830 individuals from 32 socially, linguistically, and geographically diverse endogamous populations of India. The population details and genotype distribution of functional variants (Ϫ550CϾG, Ϫ221GϾC, ϩ4CϾT, MBL2*D, MBL2*B, and MBL2*C) that affects serum MBL levels are summarized Table 5 . The frequency of low MBL2 secretor haplotypes varies significantly between Indian populations (low, 0 to 62.5%) (Fig. 3) . We did not observe low-MBL2 haplotypes in two of the investigated tribal populations (Subba and Gond), whereas an ancestral tribal population Juang revealed a high (62.5%) frequency. However, the distribution of the AO and XY diplotypes showed that the high prevalence of the low-MBL2 haplotype in Juang is mainly due to promoter variant (X, 62.50%) and not because of structural variants (O, 17.19%) (Fig. 3) . Similarly, Subba tribes had high frequencies of A (78.13%) and Y (68.75%) alleles, and the resulting major genotype YA (Fig. 3) . Further, the MBL2 exon1 variant MBL2*B is the prevalent form of structural variant in most of the Indian populations (Fig. 3) .
DISCUSSION
Mannose-binding lectin (MBL) is a soluble innate immune pathogen recognition protein that plays a vital role in defense during the early phase of infection (9) . Several studies have shown that MBL2 genetic variants regulate the MBL serum levels in different autoimmune diseases and infectious diseases, such as malaria, leishmaniasis, leprosy, tuberculosis, schistosomiasis, trypanosomiasis, and HIV infection (9, (14) (15) (16) (17) (18) (19) (20) (21) . The clinical significance of MBL2 variants varies with the disease context in different world populations (21, (47) (48) (49) .
We observed significant differences in genotype and allele frequencies among asymptomatic subjects and in patients with mild and severe malaria. The genotype and allele distribution of promoter polymorphism Ϫ221XY differed significantly between the asymptomatic and mild-malaria groups, as well as between the asymptomatic and severe-malaria groups, whereas the exon1 structural variants (MBL2*B) were associated with severe malaria only. Individuals homozygous for structural variants in exon1 (MBL2*B, MBL2*C, and MBL2*D) were rare. None of the other variations were associated with either mild or severe malaria. Earlier studies have documented the role of other functional MBL2 promoter polymorphism (Ϫ550HL) in several diseases (21, 50) ; however, we did not found any statistical significance in our study. We observed that the Ϫ221C(X) allele was found at significantly higher frequencies in malaria cases, which increases the risk for clinical malaria. We also observed that the structural MBL2 variants were significantly less frequent in asymptomatic subjects but higher in the severe-malaria group, showing that individuals with structural MBL2 variants are at higher risk for severe malaria. Thus, our findings suggest that MBL2 variants that decrease the plasma level of the functional MBL protein or encode dysfunctional proteins make their carriers susceptible to malaria. This result is in accordance with previous studies, which demonstrated that the low-serum-MBL genotype is a risk factor for malarial infection (5, 9, 32, 51); however, a study performed in Gambia and MBL2*C). We found all three structural variants in our study. The genotype YA/YA was found to be significantly less common in the severe-malaria group than in asymptomatic controls, whereas genotype XA/YO was more common. We also observed that the genotype YA/YO was significantly less common in mild-malaria cases compared to asymptomatic subjects. These findings indicate that a low-serum-MBL diplotype might be a risk factor for severe malaria while the intermediate-serum-MBL diplotype might be a risk factor for mild malaria. Several studies have shown the effects of MBL2 secretor haplotypes in disease association studies (9, 21, 32) . Our investigation of the MBL2 secretor haplotype also showed significant differences in haplotype carriages between various case-control groups. Stratification of our cohort based on MBL2 haplotypes showed that the haplotypes MBL2*LYPA and MBL2*LYQA were significantly less common in the severe-malaria group, whereas haplotype MBL2*LXPA was significantly less common in the mild-malaria group. This again elucidates that the individuals with the highserum-MBL haplotype have low risk for malaria. In addition to the eight common haplotypes reported previously (9), we observed here four novel MBL2 secretor haplotypes, MBL2*HYQA, MBL2*HYQC, MBL2*LXPB, and MBL2*LYQB, although at much lower frequencies that were independently reconfirmed by subsequent sequencing procedures. The exceptional uncharacterized secretor haplotypes MBL2*LYQB and MBL2*HXPA have also been reported in Bakola Pygmy and Moroccan Berber populations, respectively (52) .
Apart from structural variants, we did not observe any other variations that were statistically significant between the severeand mild-malaria groups. The comparison shows that the structural variants are over-represented in severe cases, while the normal variants are over-represented in the mild-malaria group, suggesting that the severity of P. falciparum malaria is inversely proportional to the serum level of functional MBL.
In the present study, among 32 Indian populations across India, we observed that the frequency of MBL2 haplotypes, which leads to low level of serum MBL, varies drastically from 0% in Subba and Gond to 62.5% in an ancestral tribal population in Juang. The prevalence of low-MBL haplotypes in Juang is mainly due to the prevalence of X and is not due to structural variants. Further, high-and low-serum-MBL haplotypes are not restricted to a particular geographic region. In the same geographic region, populations show varied prevalences of MBL2 haplotypes and, hence, may show different levels of susceptibility to malaria and other infectious diseases. These findings are in agreement with the genetic structure of Indian populations, who maintain their unique genetic architecture, mainly due to endogamy marriage practice over the last several thousand years. This has been well supported by our earlier studies with mtDNA, Y chromosome, and autosomal genetic markers (38, 39, 42, 44) . We also observed all three structural variants in exon1 (MBL2*D, MBL2*B, and malaria can progress into a more severe form and so this is true for severe to mild malaria or asymptomatic to mild malaria. Therefore, further studies on ethnically different populations, as well as larger case-control and cohort studies, are strongly recommended in order to obtain better estimates of malarial risks associated with the MBL2 polymorphism.
